Dr. Luke on Toxicities With Targeted Therapy Vs Immunotherapy in Melanoma

Source: OncLive, December 2021

Jason J. Luke, MD, FACP, director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, associate professor of medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma.

It is important to understand the difference in toxicity between targeted therapies and immunotherapies, according to Luke. Immune-related adverse effects (AEs) can include rash, colitis, or pneumonitis, and toxicities associated with BRAF and MEK inhibition tend to include various degrees of rash, pyrexia syndrome, fever, chills, and gastrointestinal issues, Luke explains.

READ THE ORIGINAL FULL ARTICLE